HSIL

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

Retrieved on: 
Tuesday, March 19, 2024
Medicine, Cervical cancer, Patient, Cancer, HPV16, School, Congress, Gynaecology, Risk, Peking Union Medical College, Woman, LEEP, Safety, Gynecologic Oncology (journal), Pathology, Recurrence, Squamous intraepithelial lesion, Acceleration, Research, Șaeș, SGO, Death, National Cancer Center, Vaccination, Molina Healthcare, Annual general meeting, Health, Obstetrics, Hysterectomy, HSIL, Public health, Infection, Incidence, LSIL, HPV, Bleeding, Physician, Birth control

This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.

Key Points: 
  • This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • Primary endpoint of the study is the proportion of responders at 6 months after the initial treatment.
  • The study is led by Dr. Jinghe Lang, an academician at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.
  • Dr. Linda Wu, Chief Development Officer of Asieris Pharmaceuticals, said, "We are extremely proud of the results from the international multicenter Phase III clinical study of APL-1702.

Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Retrieved on: 
Tuesday, March 5, 2024
Oncology, Medical Supplies, Health, Medical Devices, Research, Science, Biotechnology, Methylation, Cervical cancer, Woman, ASCL1, Dysplasia, Triage, Partnership, Multiple endocrine neoplasia, Test management, Human papillomavirus infection, Fujirebio, Risk, SCC, Biomarker, RUO, Incidence, Patient, Carcinoma, Carcinogenesis, Gene, HPV, HSIL, Host, Anal cancer, Lithium, DNA methylation, DNA, IVD, Cancer, CIN, Vaccine

Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.

Key Points: 
  • Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.
  • In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate.
  • Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer.
  • Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer.

Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN

Retrieved on: 
Thursday, February 22, 2024
Cevira, Bladder cancer, Congress, HPV, HSIL, Photocure, Mortality, Pharmaceutical industry

Read Asieris' full media release here: https://asieris.com/asieris-to-unveil-first-ever-results-of-the-internat...

Key Points: 
  • Read Asieris' full media release here: https://asieris.com/asieris-to-unveil-first-ever-results-of-the-internat...
    Cevira is a breakthrough photodynamic drug-device combination product that is being developed for non-surgical treatment of high-grade precancerous lesions of the cervix.
  • Photocure developed Cevira through Phase 1 and Phase 2 trials, and the global rights for development and commercialization were out-licensed to Asieris Meditech Co., Ltd in 2019.
  • Asieris is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases.
  • All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion

Retrieved on: 
Tuesday, January 9, 2024
Action plan, E pluribus unum, Woman, Bladder cancer, Marketing, Health, Elimination, Society, Cancer, Cervical cancer, Infection, World Health Organization, Diagnosis, NMIBC, Comparison, Cervical weakness, Multimedia, Death, ASCO, Breast cancer, Eli Lilly, Tislelizumab, Prevalence, MIBC, Neoadjuvant therapy, HPV, Human papillomavirus infection, LSIL, New Drug Application, NMPA, National Health Commission, Central China, Kidney cancer, Women's health, National Cancer Center, PD-1, WHO, Mortality, HSIL, Conditional sentence, Internet, Weak topology, Patient, Senior, State Council, NDA, Incidence, Head, National Medical Products Administration, Miscarriage

This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women's health.

Key Points: 
  • This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women's health.
  • Asieris Pharmaceuticals will leverage both in-house discoveries and external partnerships to enrich its gynecological portfolio, thereby reinforcing its leadership in women's health.
  • In November 2020, the World Health Organization (WHO) released a Global Strategy to Accelerate the Elimination of Cervical Cancer.
  • To further deliver its strategic vision and commitment in the realm of women's health, Asieris Pharmaceuticals has announced the establishment of the Women's Health Business Unit.

Fosun International has been awarded the "ESG Benchmark Awards"

Retrieved on: 
Tuesday, September 26, 2023
Benchmark, Social responsibility, Kerry Logistics, S&P Global, Welfare, Table, Education, AXA, Financial services, Culture, S&P Global 1200, COVID-19, Health promotion, Foot, Henderson Land Development, HSI, Fosun International, United Nations Global Compact, Carbon, Silver Award, Chinachem, RMB, The Bund Finance Center, Hang Seng Indexes Company, Treasury, MSCI, Sustainability, HSIL, Award, ESG, Wheelock Properties, AA, Film industry, Pharmaceutical industry

Fosun International was awarded the "ESG Benchmark Awards" Silver Award in recognition of its efforts and outstanding performances in the environmental protection, social responsibility, and corporate governance aspects.

Key Points: 
  • Fosun International was awarded the "ESG Benchmark Awards" Silver Award in recognition of its efforts and outstanding performances in the environmental protection, social responsibility, and corporate governance aspects.
  • The Awards aims at recognising excellent enterprises and organisations which dedicated in promoting sustainable development, fulfilling social responsibilities and delivering excellent corporate governance.
  • Presently, Fosun International is the only conglomerate in Greater China rated AA by MSCI ESG Ratings.
  • While developing its businesses, Fosun emphasises the use of ESG criteria to assess its own sustainable development capability and level.

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Retrieved on: 
Wednesday, September 20, 2023
Linda, Malignancy, Obstetrics, Photocure, Peking Union Medical College Hospital, Medicine, NDA, Cervical cancer, Woman, Cevira, Human papillomavirus infection, Death, Incidence, SSE, Peking Union Medical College, Patient, HSIL, Cancer, HPV, Gynaecology, Mortality, WHO, Phase, NMPA, Safety, Bladder cancer, Pharmaceutical industry, Birth control, Colposcopy

Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.

Key Points: 
  • Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.
  • This study is a prospective, randomized, double-blind, placebo-controlled international multicenter Phase III clinical trial designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • "It is exciting to see that the Phase III clinical trial for Cevira has met its primary endpoint.
  • This press release may contain product details and information which are not valid, or a product is not accessible, in your country.

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Retrieved on: 
Wednesday, September 20, 2023
Linda, Malignancy, Obstetrics, Photocure, Peking Union Medical College Hospital, Medicine, NDA, Cervical cancer, Woman, Cevira, Human papillomavirus infection, Death, Incidence, SSE, Peking Union Medical College, Patient, HSIL, Cancer, HPV, Gynaecology, Mortality, WHO, Phase, NMPA, Safety, Bladder cancer, Pharmaceutical industry, Birth control, Colposcopy

Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.

Key Points: 
  • Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.
  • This study is a prospective, randomized, double-blind, placebo-controlled international multicenter Phase III clinical trial designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • "It is exciting to see that the Phase III clinical trial for Cevira has met its primary endpoint.
  • This press release may contain product details and information which are not valid, or a product is not accessible, in your country.

New Jeeva eClinical Research Technology Enables Global Diversity Inclusion and Multi-Center Collaboration

Retrieved on: 
Wednesday, October 26, 2022
Cloud, National Institute, Time, United States Department of Health and Human Services, HSIL, Informatics, Cros, Magnetic resonance, Contract research organization, Human services, Clinical trial, Vaccine, Person, Hispanic, Patient, NIH, Research, Collection, Partnership, Technology, Georgetown University Medical Center, Degenerative disease, KCRS, FVT, Investigational New Drug, Clinical data management, CEO, Ethics, Safety, Liver, Geographic Locator Codes, Child, FDA, Conditional sentence, National Institute on Minority Health and Health Disparities, CRO, Pharmaceutical industry, Medical device, Núria, Jeeva

MANASSAS, Va., Oct. 26, 2022 /PRNewswire-PRWeb/ -- Diversity and inclusion in clinical trials are critical to achieving accurate and reliable results.(1) Participation in clinical trials is voluntary, and individuals of different ages, genders, races, ethnicities, genetic backgrounds, geographic locations, and environments will respond differently to the same treatments. An effective way to achieve diversity in clinical trials is through decentralization with standardized procedures across multiple sites.(2) To facilitate the efficient execution of multi-center clinical trials globally, Dr. Harsha Rajasimha, Founder and CEO of Jeeva Informatics, and his team have developed the modular Jeeva™ eClinical Cloud.

Key Points: 
  • Dr. Harsha Rajasimha, CEO & Founder of Jeeva Informatics, is leading the way to enable greater collaboration, diversity, inclusion, and access to decentralized clinical trials, particularly for underrepresented minorities.
  • MANASSAS, Va., Oct. 26, 2022 /PRNewswire-PRWeb/ -- Diversity and inclusion in clinical trials are critical to achieving accurate and reliable results.
  • Researchers in the U.S. and abroad have selected the Jeeva eClinical Platform for their pivotal clinical trials.
  • "Our partnership with Jeeva brings the world's first-of-its-kind clinical research service, combining MetFlux's Investigative PhysiologyTM platform with Jeeva's eClinical trials platform.

Fosun International has been awarded the "ESG Benchmark Awards - The ESG Leader" Award

Retrieved on: 
Tuesday, September 6, 2022
Benchmark, Award, HSIL, Carbon, Organization, Social responsibility, Silver Award, Artesunate, Hong Kong Stock Exchange, RNA transfection, MSCI, BioNTech, Patient, Achievement, Biophysical environment, Happiness, Hang Seng Indexes Company, Extracorporeal Life Support Organization, Treasury, ESG, Financial services in Japan, Forbes Global 2000, Ecosystem, Industry, AA, Society, Entrepreneurship, Solution, Financial services, Environmental, social and corporate governance, Fosun Pharma, Welfare, Government, FTSE Russell, Group, Institute, United Nations Global Compact, Intelligence, Forbes, Global, Collaborative Project to Increase Production of Rural Doctor, Mahidol University, Malaria, Film, Pharmaceutical industry, Lithium, Renewable energy, Health, Fosun International

Fosun International was awarded the "ESG Benchmark Awards The ESG Leader" Silver Award in recognition of its efforts and outstanding performances in the environmental protection, social responsibility, and corporate governance aspects.

Key Points: 
  • Fosun International was awarded the "ESG Benchmark Awards The ESG Leader" Silver Award in recognition of its efforts and outstanding performances in the environmental protection, social responsibility, and corporate governance aspects.
  • While developing its businesses, Fosun emphasizes the use of ESG criteria to assess its own sustainable development capability and level.
  • In 2007, Fosun International Limited was listed on the main board of the Hong Kong Stock Exchange (stock code: 00656.HK).
  • Fosun International ranks No.589 on the 2022 Forbes Global 2000 List, with a MSCI ESG rating of AA.

Photocure Partner Asieris Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial

Retrieved on: 
Tuesday, August 9, 2022
Woman, National Medical Products Administration, Photocure, Mortality, HSIL, Bladder cancer, PHO, Death, Technology, Clinical trial, Cancer, Incidence, Cervical cancer, Patient, NMPA, Oslo Stock Exchange, Safety, OSE, Solution, Pharmaceutical industry, Cevira

Additionally, Photocure received a $1 million milestone payment from Asieris related to the ongoing clinical development of Cevira.

Key Points: 
  • Additionally, Photocure received a $1 million milestone payment from Asieris related to the ongoing clinical development of Cevira.
  • APRICITY is a multicenter, prospective, double-blind, randomized controlled Phase III study further evaluating the efficacy and safety of the integrated drug-and light-delivery device Cevira in the treatment of HSIL.
  • The clinical trial was approved by the National Medical Products Administration (NMPA) in July 2020 and was conducted simultaneously at 65 sites in 8 countries including China, Germany, Hungary and the Netherlands.
  • Asieris Pharmaceuticals entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to obtain the worldwide development and commercialization of Cevira in July 2019.